

MEETING VENUE

Sala della Protomoteca - City Hall
Via del Campidoglio, 1 - 00186 Roma
Access from Scalinata del Vignola

OFFICIAL LANGUAGE

English

REGISTRATION

Registration is free and available at www.ercongressi.it – section “I nostri congressi/2025”.

CME

An application for Italian CME credits has been made as follow:

- Provider Studio ER Congressi Srl ID 828-439437
- N. 4,2 credits for Biologists, Psychologists (Psychotherapy; Psychology), Nurse, Physicians (Hematology; Geriatrics; Internal Medicine; Oncology; Radiation Therapy; Clinical Pathology; General Medicine; Continuity Of Care; Psychotherapy; Palliative Care).
- Objective: guidelines-protocols-procedures

SCIENTIFIC SECRETARIAT

Fabio Efficace
Fondazione GIMEMA,
Franco Mandelli Onlus, Roma

Massimo Breccia
Sapienza Università di Roma, Roma

LOCAL SCIENTIFIC COMMITTEE

Paola Fazi
Fondazione GIMEMA,
Franco Mandelli Onlus, Roma

Marco Vignetti
Fondazione GIMEMA,
Franco Mandelli Onlus, Roma

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via De' Poeti 1/7 - 40124 Bologna
Tel.+39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

ER Congressi
 

 **fondazione GIMEMA** onlus
per la promozione e lo sviluppo della ricerca scientifica
sulle malattie ematologiche. **FRANCO MANDELLI**



Special thanks to



SIE
Società Italiana
di Ematologia



Auspices

GIMEMA International Meeting New Frontiers in Hematologic Research: Quality of Life and Artificial Intelligence



With the unrestricted educational grant of



Johnson&Johnson

 **NOVARTIS**

abbvie

AMGEN

 **Bristol Myers Squibb®**

SERVIER
moved by you

 **sobi**
rare strength

Rome, Sala della Protomoteca

October 3, 2025

09:00am-09:30am Registration

09:30am-09:45am Welcome and greetings
M. Vignetti, *President of GIMEMA*
P.L. Zinzani, *President of Italian Society of Hematology*

09:45am-10:00am Meeting introduction
Chair: F. Efficace (*Roma*)
Co-Chair: M. Breccia (*Roma*)

10:00am-12:30pm **SESSION I**
RECENT ADVANCES IN HEMATOLOGIC RESEARCH AND QUALITY OF LIFE (QoL)

Chairpersons: F. Pane (*Napoli*), **A.M. Vannucchi** (*Firenze*),
A. Venditti (*Roma*)

10:00am-10:20am CAR-T cell therapy in hematologic malignancies and QoL findings from the GIMEMA CAR-T study
P.L. Zinzani (*Bologna*)

10:20am-10:40am Treatment advances for patients with myelofibrosis (MF) and value of patient-reported symptoms
C. Harrison (*London, UK*)

10:40am-11:00am Treatment tolerability and quality of life in patients with multiple myeloma (MM)
J.D. Peipert (*Birmingham, UK*)

11:00am-11:20am Treatment selection for patients with chronic myeloid leukemia (CML) and the role of quality of life
M. Breccia (*Roma*)

11:20am-11:40am VEXAS syndrome: state of the art research and the value of quality of life assessment
C. Gurnari (*Roma*)

11:40am-12:00pm Recent advances in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
A. Zeidan (*New Haven, USA*)

12:00pm-12:20pm The value of quality of life data in MDS and AML to boost clinical research
F. Efficace (*Roma*)

12:20pm-12:30pm Discussion

12:30pm-1:45pm Lunch

1:45pm-2:30pm

SESSION II
PATIENT ORGANIZATIONS AND EARLY PALLIATIVE CARE IN HEMATOLOGIC RESEARCH

Chairpersons: G. Caocci (*Cagliari*), **M. Luppi** (*Modena*)

1:45pm-2:05pm The unique contribution of patient organizations in hematologic research
G. Toro (*Roma*)

2:05pm-2:25pm The value of integrating early palliative care to improve patient outcomes
L. Potenza (*Modena*)

2:25pm-2:30pm Discussion

2:30pm-4:30pm **SESSION III**
DIGITAL HEALTH TOOLS AND ARTIFICIAL INTELLIGENCE (AI) IN HEMATOLOGY

Chairpersons: M.G. Della Porta (*Rozzano-MI*),
A. Piciocchi (*Roma*), **M.T. Voso** (*Roma*)

2:30pm-2:50pm The role of artificial intelligence (AI) tools to boost hematologic clinical research
M.G. Della Porta (*Rozzano-MI*)

2:50pm-3:10pm Diagnostic and prognostic prediction model studies using artificial intelligence (AI)
G.S. Collins (*Oxford, UK*)

3:10pm-3:30pm Ethics of AI use in hematology practice and clinical research
G.A. Abel (*Boston, USA*)

3:30pm-3:50pm Electronic PRO and wearables in hematologic registries
L.V. van de Poll-Franse (*Amsterdam, NL*)

3:50pm-4:10pm Unlocking the potential of synthetic patients for accelerating hematologic research
M. Cipriani (*Roma*)

4:10pm-4:30pm Discussion

4:30pm-5:00pm Conclusions and take-home messages
F. Efficace (*Roma*), **M. Breccia** (*Roma*)

